Quantifying unmet prevention needs among MSM in Europe through a multi-site bio-behavioural survey by Mirandola, Massimo et al.
1www.eurosurveillance.org
Research article
Quantifying unmet prevention needs among MSM in 
Europe through a multi-site bio-behavioural survey
Massimo Mirandola¹, Lorenzo Gios¹, Nigel Sherriff², Ulrich Marcus³, Igor Toskin⁴, Magdalena Rosinska⁵, Susanne Schink³, 
Sharon Kühlmann-Berenzon⁶, Barbara Suligoi⁷, Cinta Folch⁸, Christiane Nöstlinger9,10, Sonia Dias11, Danica Stanekova12, Irena 
Klavs13, Saulius Caplinskas14, Alexandru Rafila15, Carolina Marin16, Ivailo Alexiev17, Lev Zohrabyan18, Teymur Noori19, Cinthia 
Menel-Lemos20, on behalf of the SIALON II Network21
1. Infectious Diseases Section, Department of Diagnostics and Public Health, University of Verona, Verona, Italy
2. School of Health Sciences, University of Brighton, Brighton, United Kingdom
3. Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
4. Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland
5. Department of Epidemiology of Infectious Diseases and Surveillance, National Institute of Public Health – National Institute of 
Hygiene, Warsaw, Poland
6. Department of Public Health Analysis and Data Management, Public Health Agency of Sweden, Solna, Sweden
7. Centro Operativo AIDS, Dipartimento di Malattie Infettive, Parassitarie ed Immunomediate, Istituto Superiore di Sanità, Rome, 
Italy
8. Centre d’Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Dept Salut, 
Generalitat de Catalunya / CIBER Epidemiologia y Salud Pública (CIBERESP), Barcelona, Spain
9. Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium
10. Faculty of Psychology, University of Vienna, Austria
11. 11 Escola Nacional de Saúde Pública, Centro de Investigação em Saúde Pública & GHTM, Universidade NOVA de Lisboa, 
Portugal
12. NRC for HIV/AIDS, Slovak Medical University, Bratislava, Slovak Republic
13. National Institute of Public Health, Ljubljana, Slovenia
14. Centre for Communicable Diseases and AIDS, Mykolas Romeris University, Vilnius, Lithuania
15.  National Institute of Infectious Diseases Prof. Dr. Matei Bals, Bucharest, Romania
16. ACCEPT, Bucharest, Romania
17.  National Reference Laboratory of HIV, National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria
18. Regional Support Team Joint United Nations Programme on HIV/AIDS (UNAIDS), Moscow, Russia
19. European Centre for Disease Prevention and Control, Stockholm, Sweden
20. Consumers, Health, Agriculture and Food Executive Agency (Chafea), Luxembourg
21. Members of the the Sialon II Network have been acknowledged at the end of this article
Correspondence: Lorenzo Gios (gios.lorenzo@gmail.com)
Citation style for this article: 
Mirandola Massimo, Gios Lorenzo, Sherriff Nigel, Marcus Ulrich, Toskin Igor, Rosinska Magdalena, Schink Susanne, Kühlmann-Berenzon Sharon, Suligoi Barbara, 
Folch Cinta, Nöstlinger Christiane, Dias Sonia, Stanekova Danica, Klavs Irena, Caplinskas Saulius, Rafila Alexandru, Marin Carolina, Alexiev Ivailo, Zohrabyan 
Lev, Noori Teymur, Menel-Lemos Cinthia, on behalf of the SIALON II Network. Quantifying unmet prevention needs among MSM in Europe through a multi-site bio-
behavioural survey. Euro Surveill. 2018;23(49):pii=1800097. https://doi.org/10.2807/1560-7917.ES.2018.23.49.1800097 
Article submitted on 02 Mar 2018 / accepted on 11 Sep 2018 / published on 06 Dec 2018
Introduction: The HIV epidemic represents an impor-
tant public health issue in Europe particularly among 
men who have sex with men (MSM). Global AIDS 
Monitoring indicators (GAM) have been widely and 
jointly promoted as a set of crucial standardised items 
to be adopted for monitoring and responding to the 
epidemic. Methods: The Sialon II study, implemented 
in 13 European cities (2013-14), was a complex multi-
centre integrated bio-behavioural cross-sectional 
survey targeted at MSM, with a concomitant collec-
tion of behavioural and biological (oral fluid or blood 
specimens) data. Rigorous sampling approaches for 
hard-to-reach populations were used (time-location 
sampling and respondent-driven sampling) and GAM 
indicators were calculated; sampling frames were 
adapted to allow weighted estimates of GAM indica-
tors. Results: 4,901 MSM were enrolled. HIV preva-
lence estimates ranged from 2.4% in Stockholm to 
18.0% in Bucharest. When exploring city-level correla-
tions between GAM indicators, prevention campaigns 
significantly correlated with levels of condom use 
and level of HIV testing among MSM. Conclusion: The 
Sialon II project has made an important contribution 
to the monitoring and evaluation of the HIV epidemic 
across Europe, integrating the use of GAM indica-
tors within a second generation HIV surveillance sys-
tems approach and in participatory collaboration with 
MSM communities. It influenced the harmonisation of 
European data collection procedures and indicators 
via GAM country reporting and contributed essential 
knowledge informing the development and implemen-
tation of strategic, evidence-based HIV prevention 
campaigns for MSM.
Introduction
The HIV epidemic represents an important public 
health issue in Europe, particularly among men who 
have sex with men (MSM). For example, across the 
entire European Region, one new HIV diagnosis case 
in every four is attributable to MSM. Moreover, in 15 
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EU/EEA countries (Austria, Croatia, Cyprus, Czech 
Republic, Germany, Greece, Hungary, Ireland, Malta, 
Netherlands, Poland, Slovakia, Slovenia, Spain and 
the United Kingdom), MSM accounted for roughly 50% 
of all new HIV cases [1,2]. According to the European 
Centre for Disease Prevention and Control (ECDC) and 
the World Health Organization (WHO), the 2014 HIV 
prevalence among MSM aged 25 years or younger is 
2.9%, while for MSM older than 25 years, it is estimated 
to be 7.7%. Thirty-four percent of HIV cases attributed 
to sex between men are usually diagnosed before the 
age of 30 [1,3].
While over the last few years there has been a general 
increase in new HIV infections among MSM in the EU/
EEA, among young MSM the increase has been particu-
larly noticeable [4]. Indeed, the number of MSM aged 
20–24 years newly diagnosed with HIV almost doubled 
between 2004 and 2013, while in MSM aged 30–39 
years old there seems to be a relative stabilisation of 
new cases [1]. To reverse these trends, there is a need 
for strategic, large-scale comprehensive and comple-
mentary prevention measures such as increased HIV 
and Sexually Transmitted Infections (STIs) testing, con-
dom promotion, access to pre-exposure prophylaxis 
(PrEP) and early treatment initiations [2].
The picture is arguably even more problematic in some 
Eastern European and Central Asian countries where, 
although the HIV epidemic among this population is 
often similar, the existence of relatively more stigma-
tising environment(s) are probably less conducive to 
the reporting of data that could potentially deepen 
the understanding of mechanisms of HIV transmission 
among MSM [5].
In order to target prevention strategies effectively and 
to monitor their impact at a local/regional and country 
level, a better understanding of the epidemiological 
patterns and identification of the most affected sub-
populations, are key enabling factors in tackling the 
multifaceted HIV epidemic. In Europe this particularly 
relates to MSM and there is a clear need for a harmo-
nised collection of reliable and comparable data on 
epidemiology and coverage of prevention measures in 
this population.
Consequently, international agencies (namely, the Joint 
United Nations Programme on HIV/AIDS (UNAIDS), 
WHO and ECDC) have called for countries to use robust 
surveillance and monitoring systems that adopt com-
mon and standardised indicators [6]. A key part of this 
international effort for harmonisation is the promotion 
and implementation of second generation HIV surveil-
lance systems (SGSS), which collect and link biological 
and behavioural data [6]. The Global AIDS Monitoring 
indicators (GAM) are part of the SGSS and comprise a 
set of standardised items widely and jointly promoted 
by the WHO and UNAIDS [7,8].
However, despite concerted efforts by these interna-
tional agencies, the implementation of such a method-
ological approach is patchy and requires both adoption 
and strengthening across countries [8]. Although coun-
try reporting to the UNAIDS GAM has improved consist-
ently over the years, to date there remains considerable 
variability in response rates [8].
A recent review of the GAM reporting process has high-
lighted a lack of data relating to key populations. For 
example, in 2012, GAM data on key populations were 
reported in approximately only 30% of cases [9].
A standardised set of GAM indicators is crucial given 
their role in providing specific data and information 
to monitor the implementation of the Sustainable 
Development Goals (SDG) and the UNAIDS 90–90–
90 strategy, recently endorsed by the European 
Commission (EC) Communication on ‘Next steps for 
a sustainable European future’ [10]. The EC has co-
funded several projects in the area of HIV/AIDS, two 
of which have aimed specifically to implement a joint 
survey across different EU/EEA countries adopting the 
main principles of SGSS and the GAM approach as 
Table 1
Definitions for numerators and denominators
GAM Nominator Denominator
1.11 (Prevention 
programme)
Number of MSM who replied ‘yes’ to both questions related to the 
prevention programmes as per GAM guidelines (knowledge of HIV testing 
services and condoms received in the last 12 months in the context of broad 
prevention campaigns – outreach service)
Total number of MSM who 
participated in the survey
1.12 (Condom use) Number of MSM who reported that a condom was used the last time they had anal sex
Number of MSM who reported 
having had anal sex with a male 
partner in the last 6 months
13 (HIV testing) Number of MSM who reported having been tested for HIV during the last 12 months and who knew their results
Number of MSM included in the 
sample
1.14 (HIV prevalence) Number of MSM with a reactive HIV test (based on laboratory results) Number of MSM tested for HIV in the context of the survey
GAM: Global AIDS Monitoring indicators; MSM: men who have sex with men.
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cornerstones. The two projects are the Sialon project 
[11] and the more recent Sialon II project [12,13]. In par-
ticular, in the Sialon II project a total of 13 countries 
with very different cultural and social environments 
with 30 institutions including public health institutions 
and non-governmental organisations (NGOs) were 
involved. The meaningful participation of Lesbian-
Gay-Bisexual-Trans-plus (LGBT  +) communities in all 
participating countries has been key in designing and 
implementing the study.
The value of the Sialon II project lays in the sam-
pling approach (Time-Location Sampling (TLS) and 
Respondent-Driven Sampling (RDS)) and the use of 
GAM indicators. The methodology adopted allowed 
the weighted estimation of GAM indicators, presented 
in this manuscript. To our knowledge, this is the first 
paper delivering weighted estimates for GAM indica-
tors in a large number of European cities set within the 
framework of a SGSS specifically targeting MSM.
The objectives of this paper are to present weighted 
estimates of the GAM indicators among MSM based 
on the Sialon II bio-behavioural survey implemented 
in 13 European cities (2013-14) and to discuss the use-
fulness of these GAM indicators in monitoring the HIV 
epidemic and responses across EU countries.
Methods
Detailed descriptions of the study procedures and 
methods have been published elsewhere [12]. Here we 
present a short overview of the main methodological 
aspects.
Study design
The Sialon II study was a complex multi-centre inte-
grated bio-behavioural cross-sectional survey with a 
concomitant collection of behavioural data and biologi-
cal data (oral fluid or blood specimens).
Setting
The survey was implemented in 13 European cities. 
The decision to use TLS or RDS in each study site was 
based on preliminary formative research and organisa-
tional issues. TLS was adopted in nine cities: Brussels 
(Belgium), Sofia (Bulgaria), Hamburg (Germany), 
Warsaw (Poland), Lisbon (Portugal), Ljubljana 
(Slovenia), Barcelona (Spain), Stockholm (Sweden) and 
Brighton (United Kingdom (UK)). The setting for data 
collection included social and/or commercial venues 
and cruising settings preliminarily identified through 
formative research [14] and then selected randomly for 
data collection sampling calendars. RDS was used in 
four cities: Verona (Italy), Vilnius (Lithuania), Bucharest 
(Romania) and Bratislava (Slovakia). Regarding the lat-
ter, enrolment was based on the individuals’ social 
network and for the data collection locally accredited 
healthcare facilities (e.g. a hospital) were used. Data 
collection for all sites took place from April 2013 to 
November 2014.
Sample size
The sample size estimation was carried out based on 
the results from the former Sialon I project and other 
available studies [11]. Based on assumptions of HIV 
prevalence in the target population of at most 15%, 
a precision of 5%, a significance level of 95% and a 
design effect of 2.0 provided a random clustered sam-
ple size calculation of 392 MSM per study site. Taking 
into account the possibility of invalid samples, a final 
Table 2
Enrolment method, mean age, age group, by city, European Union cities (n = 13)
City Recruitment type Mean age (range)
Age group in years (GAM disaggregation)
Total
< 25 25 +
Barcelona TLS 37.2 (19–79) 42 360 402
Brighton TLS 35.1 (18–74) 67 344 411
Brussels TLS 34.9 (18–68) 50 341 391
Hamburg TLS 38.0 (18–79) 39 368 407
Lisbon TLS 37.9 (19–76) 35 373 408
Ljubljana TLS 30.5 (18–73) 121 273 394
Sofia TLS 29.6 (18–58) 115 296 411
Stockholm TLS 31.7 (18–81) 77 289 366
Warsaw TLS 28.8 (18–71) 92 314 406
Bratislava RDS 30.3 (18–62) 118 282 400
Bucharest RDS 30.8 (19–58) 47 134 181
Verona RDS 31.9 (18–70) 104 293 397
Vilnius RDS 30.7 (19–59) 83 239 322
GAM: Global AIDS Monitoring indicators; RDS: Respondent-Driven Sampling; TLS: Time-Location.
Cities presented with white background: TLS survey. Cities presented with light blue background: RDS survey.
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target of 408 MSM per city for TLS and 400 for RDS was 
planned.
Participants
Inclusion criteria were having had any kind of sex with 
another man during the previous year before enrol-
ment, providing informed consent and agreeing to 
donate either an oral fluid (TLS) or blood specimen 
(RDS).
The exclusion criteria were being younger than the 
legal age of consent (18 years old) or having already 
participated in the study.
Data sources/measurement
Behavioural data
Behavioural data were collected through a pen-and-
paper self-administered questionnaire. Core items were 
developed in line with the GAM indicators [7]. To allow 
for sampling weight calculations, additional items were 
included in the questionnaires on the venues attend-
ance (TLS) or on network size (RDS).
Biological data
Biological specimens were obtained from participants 
of both study arms (TLS/RDS). In cities where TLS 
was used, specimens were tested for HIV antibodies 
using Genscreen HIV 1/2 version 2, Bio-Rad (Marne 
la Roquette, France). A total IgG antibodies ELISA test 
Human IgG ELISA Kit 1x96, Quantitative/Immunology 
Consultants Laboratory was also used for oral fluid (OF) 
sample testing suitability and quality control. All HIV-
reactive samples were re-tested with Vironostika HIV 
Ag/Ab, Biomerieux (Marcy-l’Étoile, France). Samples 
reactive to the first ELISA HIV test, but negative to the 
second, were classified as negative.
In cities where RDS was used, blood specimens were 
collected and processed for serum extraction accord-
ing to the respective national guidelines for safety and 
quality assurance. Serum samples were tested with 
a HIV fourth generation ELISA/CLIA screening test. 
A Western Blot test was used to confirm the positive 
cases.
Variables
The variables used for the present analysis included 
the GAM indicators suggested for MSM target popu-
lation [15]. All proposed items included in the GAM 
guidelines for MSM were used in the survey question-
naire. Numerators and denominators were defined as 
seen in Table 1.
Statistical methods
The analysis was carried out according to the GAM indi-
cator guidelines [15]. For all indicators, estimates were 
carried out with the following age disaggregation: < 25 
years old and ≥  25 years old. Age was calculated on 
the basis of the self-reported year of birth. Analyses 
were conducted using STATA Version 14.1 (StataCorp, 
College Station, Texas, United States). To allow calcu-
lation of the sampling weights, a specific procedure 
was devised on the basis of previous publications and 
methodological guidelines [12,16,17].
For the TLS survey, individual weights were assigned 
as the inverse of the product of the following: (i) the 
probability of the participant being at the sampled 
venue given he was at the sampled venue type (num-
ber of visits to sampled venue/number of visits to all 
types of venues); (ii) the length of the sampling time 
(out of all Venue-Day-Time units on the particular day) 
and (iii) the proportion of sampled individuals during 
the event in relation to the estimated number of visi-
tors during the sampling event, a modification of the 
method proposed by Karon and Wejnert [17].
For the RDS survey, and in line with a RDS approach [18], 
weighted estimates were calculated using RDS Analyst 
(www.hpmrg.org), a suite of R commands developed by 
Handcock and colleagues (2015 RDS Analyst: Software 
for the Analysis of Respondent-Driven, Sampling Data, 
Version 0.52). Gile’s Sequential Sampler approach 
was used for calculating the sampling weights. This 
approach is based on the inclusion probabilities of 
members of the sample which are based on reported 
network sizes [16]. This method is recommended when 
the sample is a significant fraction of the target popu-
lation. Therefore, in order to use this method, popula-
tion size estimates were carried out for each city. The 
calculation was based on the total number of inhabit-
ants for the city area and the expected percentage of 
MSM (according to the consensus among the project’s 
scientists and according to the scientific literature, 
given there is currently no comprehensive and precise 
agreement among experts on MSM population size 
estimations within the general population) [19,20]. All 
point estimates were reported with their respective 
sample size, 95% Confidence Intervals (CI), and esti-
mated design effect.
Ethics
All procedures adopted in the present study were in line 
with the 1964 Helsinki declaration and its amendments. 
Survey protocols were approved by the appropriate 
ethics committee in each participating city as well as 
by both the WHO Research Project Review Panel (RP2) 
and the WHO Research Ethics Review Committee (ERC). 
The name or any other identifier of the MSM enrolled 
in the study was not collected. All respondents were 
entitled to collect their test result at a nominated cen-
tre indicated to the participant during study enrolment. 
In case of a positive result, further testing, counselling, 
clinical follow up and ARV treatment were provided in 
line with the respective national guidelines.
Results
A total of 4,901 MSM were enrolled across the 13 par-
ticipating cities. In TLS study sites, 3,596 participants 
were enrolled, while in RDS sites a total of 1,305 par-
ticipants were enrolled. Participants enrolled per 
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enrolment method/city, age mean, Min-Max, age 
group, are shown in Table 2. A detailed description of 
the sample is available in the Sialon II project report 
[13].
GAM 1.11 (Prevention programmes)
In eight of the nine cities where TLS was implemented, 
more than half of respondents answered positively to 
both questions (Table 3, GAM 1.11). The sole excep-
tion was Warsaw where 28.8% (95% CI: 23.3–34.3) 
of the participants had been reached by a prevention 
programme. Where RDS was implemented, less than 
half of the MSM answered yes to both the GAM ques-
tions, except for the older participants (≥  25 years) in 
Bucharest (50.7%; 95% CI: 38.4–62.9) and young MSM 
(< 25 years) in Vilnius (58.3%; 95% CI: 43.4–72.3).
The highest percentages of MSM reporting to be 
reached with an HIV prevention programme in the 
last 12 months were reported in Sofia and Hamburg 
(88.4%; 95% CI: 82.9–94.1 and 81.4%; 95% CI: 77.6–
85.1 respectively). In Bratislava and Warsaw, the low-
est proportions of MSM participating in the survey 
had been reached by an HIV prevention programme 
(22.6%; 95% CI: 17.0–26.8 and 28.8%; 95% CI: 23.3–
34.3, respectively).
In all cities (except Brighton, Hamburg and Lisbon), 
older participants (≥ 25 years) had been reached more 
over the last 12 months than the younger participants 
(<  25 years), although differences between these age 
categories were small in most cities.
GAM 1.12 (Condom use)
Condom use according to the GAM definition, ranged 
from 45.2% (95% CI: 38.1–51.4) in Bratislava to 69.6% 
in Lisbon (95% CI: 64.5–74.3) (Table 3). With the excep-
tion of a few sites (Bratislava, Bucharest, Lisbon, 
Verona and Warsaw) condom use was higher for the 
young MSM category (<  25 years). Among older MSM 
(≥ 25 years), estimates of condom use varied between 
46.7% in Bratislava (95% CI: 38.5–54.8) to 72.0% in 
Lisbon (95% CI: 65.2–77.9). It should be noted that for 
some cities, the number of participants in the younger 
age group was low and therefore the precision of the 
estimates is reduced.
GAM 1.13 (HIV testing)
The level of HIV testing as per GAM guidelines is 
reported in  Table 3. The highest proportions of par-
ticipants (total) reporting having received an HIV test 
within the last 12 months and who also knew the result 
of that test, were reported in Brussels (68.1%; 95% CI: 
56.4–79.8) and Barcelona (63.0%; 95% CI: 52.6–73.4). 
In Lisbon only 21.1% (95% CI: 12.5–29.8) of younger men 
reported a HIV test with the collection of the test result 
in the last year, which represented the lowest levels 
in the study. The second lowest estimate after Lisbon 
was found in Bratislava with 29.0% (95% CI: 19.1–39.0) 
followed by Brighton 36.1% (95% CI: 22.7–49.6) and 
Bucharest 39.0 (95% CI: 21.8–56.2). In several cities 
there were significant differences between age groups 
with regard to receiving an HIV test within the last 12 
months and knowing the results. Participants from 
Brussels, Lisbon, and Warsaw reported differences 
greater than 20% for the two age groups.
GAM 1.14 (HIV prevalence)
HIV prevalence was calculated based on the oral fluid-
based laboratory testing for TLS and from serum-based 
laboratory tests for RDS. HIV prevalence estimates var-
ied by city with the lowest level reported in Stockholm 
(2.4%; 95% CI: 1.1–5.2) and the highest level in 
Bucharest (18.0%; 95% CI: 9.1–27.0) (Table 3). Five cit-
ies had an HIV prevalence between 10–20% (Brussels, 
Barcelona, Lisbon, Brighton, Bucharest), three cit-
ies between 5–10% (Hamburg, Warsaw, Verona), and 
five cities below 5% (Stockholm, Vilnius, Ljubljana, 
Bratislava and Sofia).
City-level correlations between GAM indicators
When exploring city-level correlations between GAM 
indicators (Figure) a significant correlation was found 
between prevention programmes indicator (defined as 
condom availability and testing site knowledge) and HIV 
testing (correlation coefficient 0.52, p-value  =  0.006). 
In addition, a correlation was found between preven-
tive programmes indicator and condom use (correla-
tion coefficient 0.45, p-value  =  0.022). Data suggest 
that the higher the prevention programmes indicator 
the higher the level of condom use and testing among 
MSM, in both age groups.
Discussion
HIV remains a public health priority in the EU and the 
data from the Sialon II study has made an important 
contribution to the monitoring and evaluation of the 
HIV epidemic across Europe, by integrating the use of 
GAM indicators within a second generation HIV surveil-
lance systems approach and in participatory collabo-
ration with MSM communities. It has influenced the 
harmonisation of European data collection procedures 
and indicators via GAM country reporting and contrib-
uted essential knowledge informing the development 
and implementation of strategic, evidence-based HIV 
prevention campaigns for MSM.
The percentage of MSM reached with prevention pro-
grammes (as measured by GAM 1.11) showed sig-
nificant differences both between and within cities. 
Although the use of different sampling methods can 
partially explain some of the differences between RDS 
vs TLS cities, the comparison among cities surveyed 
with the same sampling methodology provides valid 
indications on MSM prevention needs. In Warsaw, 
the number of individuals reached with prevention 
programmes is generally low, particularly for younger 
MSM. With the exception of Brighton, Hamburg, Lisbon 
and Vilnius, older MSM seem to be reached more fre-
quently compared with younger MSM. Cities surveyed 
using RDS present, in general, a lower number of MSM 
reached with prevention programmes, and with the 
exception of Vilnius (where a specific programme was 
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run by an NGO before and during the data collection 
period), younger MSM showed the lowest level. These 
estimates are consistent with the literature and suggest 
the need for targeted prevention programmes tailored 
to locations and communities that can also accommo-
date for the needs of sub-populations, such as young 
MSM, MSM who are tourists and bisexuals [21,22].
Data focusing on the GAM 1.12 (Condom use) indicate 
that in the majority of the surveyed cities, condom use 
with any kind of partner was lower for younger men. 
However, the sample sizes for younger men were small 
for several cities and the association between age and 
condom use was not consistent across all study cities. 
In another publication based on the same Sialon-II-
dataset, authors looked at condom use from another 
perspective e.g. any anal intercourse without a con-
dom during the previous 6 months and not just from 
the last sexual encounter. The authors reported that 
almost half of the HIV-uninfected individuals reported 
condomless anal intercourse (CLAI). This was reported 
slightly more often by men living in Central European 
study cities and more frequently with steady partners 
compared with non-steady partners [23].
Based on the estimates of this GAM indicator there 
is a clear need to either increase condom use among 
younger men or to complement prevention strate-
gies by providing meaningful access to other similarly 
effective HIV prevention tools such as HIV pre-expo-
sure prophylaxis. Despite the fact that condom and 
lubricant distribution is often considered a simple and 
somewhat naïve approach to facilitate condom use, it 
is commonly acknowledged in the literature that fear of 
disapproval and discrimination by healthcare providers 
can deter gay, bisexual and other MSM from accessing 
mainstream health services [18]. Indeed, this limita-
tion, could reduce access to free condom distribution, 
as well as low threshold HIV and STIs testing in health-
care settings [24].
A study by Marcus et al. [25] modelling the relation-
ship between unprotected anal intercourse (UAI) and 
HIV disclosure with the same study dataset, found that 
among those respondents being aware of being HIV 
positive, condom use with steady partners was higher 
than among HIV negative men. However, condom use 
with non-steady partners was also lower. Men unaware 
of being infected with HIV reported the lowest condom 
use with non-steady partners [23,25].
It is possible that a large number of MSM are unaware 
of their HIV status. It is estimated that in western and 
central Europe a noteworthy number of people at risk 
are not getting tested or can experience difficulties in 
being tested for HIV and STIs [2]. Based on surveillance 
data, ECDC estimates that a number of European coun-
tries may have a considerable proportion of late HIV 
diagnoses [2]. The testing behaviour as measured by 
the GAM 1.13 depicts a very different situation among 
the surveyed cities. In Barcelona, Hamburg, Sofia, 
Stockholm and Verona, approximately half of the par-
ticipants (all ages) reported having received an HIV test 
within the last 12 months and knew the result of that 
test. In Brighton, Brussels and Warsaw more than half 
of older participants reported a known HIV test result 
within the last 12 months while among younger par-
ticipants, it was below that level. In Lisbon only one 
in five younger men reported a known HIV test result 
in the last year which represented the lowest levels in 
the study.
In several cities there were differences between the 
two age groups with regards to receiving an HIV test 
within the last 12 months and knowing the results. 
For instance, participants from Brighton, Brussels, 
Lisbon, and Warsaw all reported differences of greater 
than 20% for the two age groups; however, consid-
ering the time span is limited to the last 12 months, 
the differences cannot be directly attributed to the 
age effect where, for example, older individuals may 
have had an increased opportunity to be tested over 
time. Furthermore, older participants were tested more 
frequently and within a shorter timeframe than the 
younger men, suggesting that increasing access to cul-
turally sensitive HIV counselling, testing and antiretro-
viral therapy for MSM, found to have HIV, is an urgent 
health priority particularly for the younger generations. 
The current levels of HIV testing are insufficient to link 
gay, bisexual and other MSM with appropriate health-
care support shortly after acquiring HIV infection. 
Therefore, currently, testing frequencies can remain 
insufficient to effectively reduce the period of infec-
tiousness of people who newly acquire HIV.
Alternative approaches such as the use of point of care 
tests (PoCTs) for HIV and STIs in low threshold com-
munity testing and LGBT venue-based testing, home 
collection testing, and HIV self-testing may represent 
effective approaches to increase diagnosis and linkage 
to care.
Figure 
HIV testing (GAM 1.13) vs prevention programmes (GAM 
1.11), European Union cities (n=13)
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The problem of late diagnosis reflects a lack of access 
to and uptake of HIV testing and counselling services in 
many countries [26]. A late diagnosis also means that a 
person has remained unaware of their HIV status for an 
indeterminate length of time, thus increasing the risk 
of transmitting the virus. The most recent surveillance 
data showed that despite significant efforts dedicated 
to the prevention and control of HIV, the rate of new 
HIV diagnoses has not substantially declined in the 
EU/EEA, but it has increased substantially over the last 
decade in the European Region.
Although HIV prevalence as an epidemic indicator 
is not a good parameter of the HIV infection spread 
dynamic, it can be helpful to provide an indirect pic-
ture of the epidemic history and patterns for some cit-
ies. HIV prevalence estimates (GAM 1.14), as measured 
by testing biological specimens (and not self-reported 
serological status), highlight critical levels of HIV infec-
tions across Europe among MSM communities despite 
valuable and concerted public health efforts [15].
Brussels, Barcelona, Lisbon, Brighton and Bucharest 
when considered globally, present relatively high HIV 
prevalences within the range of 10–20%. That said, 
the HIV prevalence estimate for Bucharest is probably 
less reliable and interpretable compared with the other 
cities for two main reasons: the existence of an osten-
sible MSM sub-sample of injecting drug-users within 
the city sample, and the fact that the target number of 
MSM to be recruited was not reached (less than 50% of 
the estimated target sample was recruited). Compared 
to these relatively high HIV prevalences, more ‘inter-
mediate’ levels of HIV prevalence were evident in four 
other participating cities (Hamburg, Warsaw, Verona, 
and Sofia) where it ranged from 5 to 10%. Finally, in the 
cities of Stockholm, Vilnius, Ljubljana, and Bratislava, 
relatively lower HIV prevalences were observed with 
results below 5%. Other smaller studies carried out in 
some of these cities (with different or similar sampling 
methods) have produced similar results [11,27].
When exploring city-level correlations between GAM 
indicators, the data confirmed that prevention pro-
grammes correlate with both the level of condom use 
and of HIV testing among MSM, which might war-
rant additional efforts in implementing preventative 
actions. Despite numerous interventions targeting 
the behaviour, knowledge and attitudes of MSM, an 
increase of STIs and HIV diagnoses have been recently 
observed. Outbreaks of syphilis, lymphogranuloma 
venereum (LGV), hepatitis C viral infection (HCV) and 
other STIs have been reported in multiple European 
cities, possibility as a result of risky sexual behaviour 
and extensive sexual networking [26], but also may be 
due to an increase in active offering of HIV and STI’s 
testing over the years.
A higher treatment coverage and higher percentage 
of HIV-positive MSM with undetectable viral load was 
attained in some Western European cities (Brussels, 
Hamburg, Brighton and Verona), indicating that when 
the service provision is proactive and the treatment 
widely available, the link between testing and treating 
can effectively influence the HIV epidemic.
Generalisability and limitations
To our knowledge, this is the first paper presenting 
weighted estimates produced as a result of a stand-
ardised collection of GAM indicators for MSM in a 
large number of European cities adopting a common 
SGSS approach. The use of this approach (SGSS and 
GAM Indicators) and the active participation of key 
LGBT community stakeholders in the project’s design 
and implementation, represent an asset that provides 
potentially usable data for both public health authori-
ties and NGOs in each partner country.
The use of TLS and RDS methodologies within the 
context of a bio-behavioural survey using a participa-
tory approach have allowed hidden and different sub-
groups of MSM to be reached; groups that are usually 
more difficult to access through surveillance studies 
[28]. Nevertheless, there are some limitations that 
should be taken into account when interpreting the 
results.
First, data can only be generalised to the particular 
MSM attending the gay venues in each study site (in 
the case of TLS survey) and only to those MSM socially 
linked to the gay community for each specific site (in 
case of the RDS survey). It has also been shown in 
other studies that these two sampling methods can 
result in different sample characteristics and the dif-
ferences may persist even after applying weighting cor-
rections [28].
Second, the generalisability of the findings may also 
be limited by contextual factors not measured in this 
survey (e.g. legislation and social norms) and an eco-
logical fallacy cannot be excluded.
Third, an additional source of bias limiting generalisa-
bility relates to the self-reported behavioural data. This 
is of course an issue common to all surveys covering 
the self-reporting of sensitive information. However, 
the anonymity of the data collected and the self-admin-
istration of the questionnaire, with the careful design 
of the questionnaire items developed and validated in 
all cities with the involvement of the LGBT community, 
may well have reduced any social desirability effect 
[29]. It is also worth noting that no difficulties or limi-
tations were reported by either respondents or data 
collectors with regards to the use of the GAM indica-
tors (both TLS and RDS) in terms of interpretation and 
utility of the items and related indicators.
Fourth, the percentage of participants who reported 
ever having injected drugs ranged from 1.2% in 
Bratislava to 19.3% in Bucharest. In the latter, esti-
mates might be difficult to be generalised due to this 
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sub-population of injecting drug users (IDU)-MSM and 
to the fact that the target sample was not reached.
Fifth, the precision of the estimates were in some 
cases not optimal, particularly for the group of younger 
MSM, due to relatively small sample sizes (< 50) and the 
potential for sampling bias in some cities.
Finally, an isolated limitation to the validity of the sur-
vey relates to Sofia (Bulgaria) where, due to an incor-
rect translation in the items questionnaire related to 
GAM 1.13, the indicator could not be estimated.
Conclusions
The Sialon II project and the data generated through 
its implementation represent a collaborative and sci-
entifically robust contribution to the monitoring and 
evaluation of the HIV epidemic across Europe, integrat-
ing the use of GAM indicators within a SGSS approach 
with active community involvement. The data collected 
provide new evidence for appropriate planning of HIV 
prevention campaigns among MSM, clearly respond-
ing to the urgent need of concerted use of common 
indicators, with a particular focus on most at risk pop-
ulations such as MSM [9]. The project has actively con-
tributed to: (i) common procedures piloting (including 
most-advanced sampling methods, standards research 
algorithms, advanced laboratory diagnostics); (ii) har-
monised data collection, involving experts from differ-
ent institutions and with different backgrounds; and 
(iii) GAM country reporting, with specific reference to 
MSM.
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